SEC Filing Summary for Barry Templin

Barry Templin, EVP, Chief Technology Officer of PROCEPT BioRobotics Corp, was granted 26,246 shares of Common Stock and 36,312 Stock Options on August 13, 2026. The Common Stock grant has a transaction value of $0 and is subject to vesting over time, with one-quarter vesting on August 13, 2027, and the remainder vesting quarterly over 36 months. The Stock Options also have a transaction value of $0, with an exercise price of $21.95. These options vest over four years, with 1/48th vesting monthly from August 13, 2026. Both grants are subject to Mr. Templin continuing as a service provider and are intended to be partially in lieu of his expected 2027 grant.